An observational study to identify the prevalence of thrombocytopenia and anti‐PF4/polyanion antibodies in Norwegian health care workers after COVID‐19 vaccination-Reference-Cited by-同舟云学术

An observational study to identify the prevalence of thrombocytopenia and anti‐PF4/polyanion antibodies in Norwegian health care workers after COVID‐19 vaccination

Published:2021-05-18 Issue:7 Volume:19 Page:1813-1818
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:J. Thromb. Haemost.

Author:

Sørvoll Ingvild Hausberg¹,Horvei Kjersti Daae¹,Ernstsen Siw Leiknes¹,Lægreid Ingvild Jenssen¹,Lund Svetlana¹,Grønli Renathe Henriksen¹,Olsen Magnus Kringstad²,Jacobsen Hege Karine²,Eriksson Anna²,Halstensen Anne Marie²,Tjønnfjord Eirik³,Ghanima Waleed⁴⁵,Ahlen Maria Therese¹^ORCID

Affiliation:

1. Norwegian National Unit for Platelet Immunology Department of Laboratory Medicine University Hospital of North Norway Tromsø Norway

2. Department of Research Østfold Hospital Grålum Norway

3. Department of Emergency Medicine Østfold Hospital Grålum Norway

4. Department of Medicine, Hematology and Research Østfold Hospital Grålum Norway

5. Department of Haematology Institute for Clinical Medicine University of Oslo Oslo Norway

Funder

Helse Nord RHF

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jth.15352

Reference13 articles.

1. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

2. Signal assessment report on embolic and thrombotic events (SMQ) with COVID‐19 vaccine (ChAdOx1‐S [recombinant]) – COVID‐19 vaccine AstraZeneca (other viral vaccines) EMA/PRAC/157045/2021.https://www.ema.europa.eu/en/documents/prac‐recommendation/signal‐assessment‐report‐embolic‐thrombotic‐events‐smq‐covid‐19‐vaccine‐chadox1‐s‐recombinant‐covid_en.pdf. Accessed April 1 2021.

3. Thrombotic thrombocytopenia after ChAdOx1 nCov‐19 vaccination;Greinacher A;N Engl J Med

4. Thrombosis and thrombocytopenia after ChAdOx1 nCoV‐19 vaccination;Schultz NH;N Engl J Med

5. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV‐19 vaccination;Scully M;N Engl J Med

Cited by 82 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-PF4 positivity and platelet activation after Ad26.COV2·S vaccination in Brazil;Vaccine;2024-11

2. Neurovascular Adverse Effects of Sars-Cov-2 Vaccination;Drug Design, Development and Therapy;2024-05

3. Thrombosis with thrombocytopenia syndrome (TTS) and vaccine-induced immune thrombocytopenia and thrombosis (VITT): Brighton Collaboration case definitions and guidelines for data collection, analysis, and presentation of immunisation safety data;Vaccine;2024-03

4. Vaccine-induced (immune) thrombotic thrombocytopenia (VITT): Diagnosis, guidelines, and reporting;Management, Body Systems, and Case Studies in COVID-19;2024

5. Transient Autoreactive PF4 and Antiphospholipid Antibodies in COVID-19 Vaccine Recipients;Vaccines;2023-12-14